The recently-revised regulations to the Stark Physician Self-Referral Law have implications that extend beyond clinicians to medtech companies, particularly as the healthcare system increasingly evolves from volume to value-based programs. These expert healthcare attorneys explain why it is essential that medtech companies understand the full ramifications of this law’s current standards. By By Melissa Hudzik, Esq., and Jeff Weinstein, Esq., Wilson Sonsini Goodrich & Rosati.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market PathwaysStart Trial
NeuTigers’ miniaturized neural networks allow wearable point-of-care devices like wristwatches to collect and analyze data on the spot. The first application among many possible is a new screening method for COVID-19 infection.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.Learn More
Jeff Shuren on the toils of COVID; An expert panel discusses medtech’s post-COVID rebound; 2020 was a record year for FDA device approvals; Scott Gottlieb on the pandemic’s effect on HealthTech innovation. Excerpts from the latest coronavirus analysis in MedTech Strategist and Market Pathways.